SLS-005 Earns Orphan Drug Status in Europe

SLS-005 Earns Orphan Drug Status in Europe

295841

SLS-005 Earns Orphan Drug Status in Europe

The European Medicines Agency (EMA) has granted orphan drug designation to Seelos Therapeutics‘ investigational therapy SLS-005 for the treatment of amyotrophic lateral sclerosis (ALS), the company announced in a press release. Orphan drug status in Europe is given to medicines with the potential to be safe and effective treatments for rare, life-threatening, or chronically debilitating conditions affecting no more than one every in 2,000 people. It provides companies with a range of incentives, including assistance…

You must be logged in to read/download the full post.